Mitochondrial Biomarkers in Huntington's Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

27 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-04-04

Study Completion Date

2022-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to discover a panel of mitochondrial metabolomics biomarkers for Huntington's disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Brain Study of Patients With Frontal Lobe Dementia and Parkinsonian Disorders

NCT00001178

Alzheimer's Disease Dementia Down's Syndrome

TERMINATED

A Study of Brain Imaging With Nuclear Medicine Technology in Individuals With and at Risk for Parkinson's Disease

NCT00117819

Parkinsonian Syndrome

COMPLETED PHASE2

Deep Brain Stimulation Treatment for Chorea in Huntington's Disease

NCT04244513

Huntington Disease Deep Brain Stimulation

UNKNOWN NA

Multicenter Study of Blood Biomarkers of Mitochondrial and Peroxisomal Metabolism to Differentiate Idiopathic Parkinson's Disease From Related Conditions

NCT05110547

Idiopathic Parkinson Disease Parkinsonian Syndrome

UNKNOWN

Modulatory Effects of Deep Brain Stimulation on Cerebral Cortical Activity

NCT04361955

DBS Parkinson Disease Essential Tremor +1 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This investigator-initiated, single-site longitudinal study seeks to assess the utility of mitochondrial metabolomics -- panels of small molecules that affect mitochondrial function -- to diagnose pre-symptomatic, pre-manifest, and symptomatic Huntington's disease and serve as biomarkers for HD severity and progression. It also seeks to demonstrate that this novel biomarker in the blood has comparable value to the same analysis in spinal fluid. This research study involves 3-4 visits over 18 months. Forty volunteers with HD and 25 volunteers without HD will be included. Volunteers who have HD will have a physical examination and blood draw at each study visit. Some participants will also volunteer for optional lumbar puncture.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Huntington Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Huntington's disease (HD)

people with HD

lumbar puncture

Intervention Type DIAGNOSTIC_TEST

Some participants will have an optional lumbar puncture

Controls without HD

people without HD

lumbar puncture

Intervention Type DIAGNOSTIC_TEST

Some participants will have an optional lumbar puncture

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

lumbar puncture

Some participants will have an optional lumbar puncture

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 20 to 85
* Montreal Cognitive Assessment score \>10
* HD subjects had onset of HD symptoms after the age of 20
* HD subjects with Diagnostic Confidence Level (DCL) of 0-3 (pre-symptomatic or pre-manifest) must have at least 40 CAG repeats on one HTT allele
* HD subjects with Diagnostic Confidence Level (DCL) of 4 (manifest) must have at least 36 CAG repeats on one HTT allele
* Controls are asymptomatic without family history of HD or have \<36 CAG repeats on both HTT alleles with family history of HD

Exclusion Criteria

* HD subjects who did not already have genetic testing are excluded from this study
* Pregnancy or plans to become pregnant during the study
* Investigational drugs within 3 months of screening visit
* Alcohol or illicit drug abuse or dependence
* Other genetic or neurological disorders
* Other medical or psychiatric illness that in the investigator's judgement will prevent ability to tolerate or undergo study procedures
* For those volunteering for lumbar puncture (LP), bleeding disorders or excessive bleeding, anticoagulation, aspirin if unable to safely stop taking it at least 7 days prior to LP, other antiplatelet medications, inability to tolerate LP, allergy to local anesthetic or chlorhexidine, major lumbar spine deformity, low platelets or abnormal coagulation factors PT/APTT

Minimum Eligible Age

20 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes